Yi Qingqing sold $66K of ONC

BeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

BeOne Medicines (ONC) reported positive Phase III trial results for Ziihera, showing improved overall survival in HER2+ gastroesophageal cancer patients when combined with chemotherapy. The study met its primary endpoint, demonstrating statistical significance and clinical benefit over trastuzumab plus chemotherapy.

President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.

Nine drugmakers, including Alcon (ALC), Astellas, BeOne Medicines (ONC), BridgeBio (BBIO), and Teva (TEVA), agreed to lower U.S. drug prices and invest $19.6B in U.S. factories. Shares showed mixed after-hours reactions. The deals follow earlier agreements with larger pharma companies, covering 89% of the branded drug market.

BeOne Medicines reported positive Phase 3 trial results for ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), in HER2+ gastroesophageal cancer. The study met its primary endpoint, showing statistically significant overall survival benefits. The FDA recently approved these regimens for first-line treatment. BeOne has rights to ZIIHERA in Asia, Australia, and New Zealand.